Published in Clin Exp Immunol on July 01, 1981
Cellular immunity in glomerulonephritis. Am J Pathol (1982) 0.99
Identification of the lymphokine soluble immune response suppressor in urine of nephrotic children. J Clin Invest (1985) 0.85
T cell CD3 receptor zeta (TCRzeta)-chain expression in children with idiopathic nephrotic syndrome. Pediatr Nephrol (2008) 0.76
Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet (1974) 4.02
Controlled trial of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood. Lancet (1970) 2.34
Isolation of an immunosuppressive peptide fraction from human plasma. J Immunol (1973) 1.70
In vitro suppression of the lymphocyte response to tuberculin by live measles virus. Proc Soc Exp Biol Med (1966) 1.39
Purification and properties of a lymphocyte inhibition factor from human serum. Clin Exp Immunol (1973) 1.37
Derangements of immunoglobulin levels, phytohemagglutinin responsiveness and T and B cell markers in Down's syndrome at different ages. Eur J Immunol (1975) 1.24
Inhibition of lymphocyte blastogenesis by plasma of patients with minimal-change nephrotic syndrome. Lancet (1976) 1.22
Lymphocyte suppression associated with alpha globulin. Changes in cellular immunity. Cell Immunol (1974) 1.10
Acute nephrotic syndrome as a manifestation of active Hodgkin's Disease. Report of four cases and review of the literature. Am J Med (1971) 1.08
Immunoregulatory properties of human plasma in very low density lipoproteins. J Immunol (1977) 1.08
A serum inhibitor of blastogenesis in idiopathic nephrotic syndrome transferred by lymphocytes. Clin Immunol Immunopathol (1979) 1.03
Serum albumin is essential for in vitro growth of activated human lymphocytes. J Exp Med (1975) 0.98
Uptake of transferrin-bound zinc by human lymphocytes. Cell Immunol (1978) 0.94
Lymphocyte subpopulations in minimal-change nephropathy. Nephron (1980) 0.93
Inhibitory factors of lymphocyte transformation in sera from patients with minimal change nephrotic syndrome. Clin Nephrol (1980) 0.93
Inhibition of lymphoproliferation by hyperlipoproteinemic plasma. J Clin Invest (1976) 0.89
Lipoprotein profiles in adult nephrotics. Mayo Clin Proc (1975) 0.88
Direct suppression of lymphocyte induction by the immunoregulatory human serum low density lipoprotein, LDL-In. J Immunol (1980) 0.86
Zinc transferrin. Enhancement of nucleic acid synthesis in phytohemagglutinin-stimulated human lymphocytes. Cell Immunol (1974) 0.85
Further studies on the mechanism of suppression of human lymphocyte transformation by human alpha fetoprotein. J Allergy Clin Immunol (1980) 0.84
Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell (2000) 9.99
Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum (1997) 5.57
Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature (1993) 4.39
Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature (1995) 2.93
Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum (1991) 2.91
Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol (2001) 2.85
Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science (1995) 2.79
High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med (1997) 2.73
Immunodeficiency with hyper-IgM (HIM). Immunodefic Rev (1992) 2.67
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol (2003) 2.63
Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. Clin Exp Rheumatol (2001) 2.55
Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc Natl Acad Sci U S A (2001) 2.39
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol (2006) 2.19
Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest (1997) 2.11
Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer (2008) 1.88
Genomic structure and identification of novel mutations in usherin, the gene responsible for Usher syndrome type IIa. Am J Hum Genet (2000) 1.76
Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum (2008) 1.69
Localization of Usher syndrome type II to chromosome 1q. Genomics (1990) 1.67
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol (2007) 1.58
Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet (1989) 1.57
Health-related quality of life of patients with juvenile idiopathic arthritis coming from 3 different geographic areas. The PRINTO multinational quality of life cohort study. Rheumatology (Oxford) (2006) 1.55
Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol (1990) 1.53
Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest (1994) 1.53
Rapid methods to extract DNA and RNA from Cryptococcus neoformans. FEMS Yeast Res (2001) 1.52
Methotrexate in juvenile idiopathic arthritis: answers and questions. J Rheumatol (2000) 1.51
Antiphospholipid antibodies in paediatrics. Eur J Pediatr (1994) 1.46
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer (2009) 1.46
Factor V Leiden mutation in a case with ischemic stroke: which relationship? A case report. Angiology (1998) 1.45
Spontaneous NBT reduction by monocytes as a marker of disease activity in children with histiocytosis. Br J Haematol (1990) 1.45
Three newly delimited species of Saccharomyces sensu stricto. Antonie Van Leeuwenhoek (1987) 1.43
Prevalence and diagnosis of celiac disease in IgA-deficient children. Ann Allergy Asthma Immunol (1996) 1.41
Vertebral and carotid artery dissection following chiropractic cervical manipulation. Neurosurg Rev (1999) 1.38
Monocytes from Wiskott-Aldrich patients display reduced chemotaxis and lack of cell polarization in response to monocyte chemoattractant protein-1 and formyl-methionyl-leucyl-phenylalanine. J Immunol (1998) 1.37
Positive selection in autoimmunity: abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. Nat Med (1995) 1.36
In-utero transplantation of parental CD34 haematopoietic progenitor cells in a patient with X-linked severe combined immunodeficiency (SCIDXI). Lancet (1996) 1.35
Early predictors of outcome in juvenile idiopathic arthritis. Clin Exp Rheumatol (2004) 1.34
Structural and functional basis for JAK3-deficient severe combined immunodeficiency. Blood (1997) 1.34
Search for new particles in two-jet final states in 7 TeV proton-proton collisions with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.32
Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. II. Early predictors of outcome. J Rheumatol (1997) 1.32
Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis (2004) 1.30
[Leishmania tropica in Morocco. III--The vector of Phlebotomus sergenti. Apropos of 89 isolates]. Ann Parasitol Hum Comp (1991) 1.27
Intrathymic restriction and peripheral expansion of the T-cell repertoire in Omenn syndrome. Blood (1999) 1.27
Immunity in Down's syndrome. Eur J Pediatr (1978) 1.26
Serum IgG subclass concentrations in healthy subjects at different age: age normal percentile charts. Eur J Pediatr (1989) 1.25
Leishmania-human immunodeficiency virus coinfection in the Mediterranean basin: isoenzymatic characterization of 100 isolates of the Leishmania infantum complex. J Infect Dis (1995) 1.25
Derangements of immunoglobulin levels, phytohemagglutinin responsiveness and T and B cell markers in Down's syndrome at different ages. Eur J Immunol (1975) 1.24
Diabetes, cardiovascular risk factors and idiopathic sudden sensorineural hearing loss: a case-control study. Audiol Neurootol (2009) 1.24
Immune-mediated inner ear disease. Acta Otolaryngol (2006) 1.23
Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr (1996) 1.23
Facts, myths and legends on the prime industrial microorganism. J Ind Microbiol (1995) 1.22
Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome status. J Rheumatol (1997) 1.21
Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol (2006) 1.21
A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis Rheum (2008) 1.20
The enantiomers of phenprocoumon: pharmacodynamic and pharmacokinetic studies. Clin Pharmacol Ther (1976) 1.17
Serum interleukin-6 levels and joint involvement in polyarticular and pauciarticular juvenile chronic arthritis. Clin Exp Rheumatol (1993) 1.16
Systematic review of the literature on the clinical effectiveness of the cochlear implant procedure in paediatric patients. Acta Otorhinolaryngol Ital (2011) 1.16
Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol (2009) 1.14
Gene mapping of Usher syndrome type IIa: localization of the gene to a 2.1-cM segment on chromosome 1q41. Am J Hum Genet (1995) 1.14
[Leishmania tropica in Morocco. IV--Intrafocal enzyme diversity]. Ann Parasitol Hum Comp (1991) 1.14
Auditory and academic performance of children with unilateral hearing loss. Scand Audiol Suppl (1988) 1.13
Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Italian Pediatric Rheumatology Study Group. Ann Rheum Dis (1998) 1.12
Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. J Pediatr (1998) 1.12
Osteoblastoma-like osteosarcoma. The Rizzoli Institute experience. Mod Pathol (1993) 1.12
Effect of caroxazone, a new antidepressant drug, on monoamine oxidases in healthy volunteers. Br J Clin Pharmacol (1981) 1.11
The endoplasmic reticulum-sarcoplasmic reticulum connection: distribution of endoplasmic reticulum markers in the sarcoplasmic reticulum of skeletal muscle fibers. Proc Natl Acad Sci U S A (1992) 1.10
Correlation between conventional disease activity measures in juvenile chronic arthritis. Ann Rheum Dis (1997) 1.10
High-dose intravenous gammaglobulin therapy for passive immune thrombocytopenia in the neonate. J Pediatr (1983) 1.10
Elevated circulating interleukin-7 levels in patients with systemic juvenile rheumatoid arthritis. J Rheumatol (1995) 1.10
Psychological profile and social behaviour of working adults with mild or moderate hearing loss. Acta Otorhinolaryngol Ital (2008) 1.09
PRINTO/PRES international website for families of children with rheumatic diseases: www.pediatric-rheumatology.printo.it. Ann Rheum Dis (2005) 1.09
Unilateral microfibrillar abnormalities in a case of asymmetric Marfan syndrome. Am J Hum Genet (1990) 1.08
Pharmacokinetic studies of 4'-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases. Cancer Treat Rep (1982) 1.08
Ontogeny of secretory immunity: levels of secretory IgA and natural antibodies in saliva. Pediatr Res (1980) 1.08
Electrophoretic karyotyping as a taxonomic tool in the genus Saccharomyces. Antonie Van Leeuwenhoek (1993) 1.08
Intravenous gammaglobulin therapy for prophylaxis of infection in high-risk neonates. J Pediatr (1987) 1.07
Clinical presentation and pathogenesis of cold-induced autoinflammatory disease in a family with recurrence of an NLRP12 mutation. Arthritis Rheum (2011) 1.06
Ineffective expression of CD40 ligand on cord blood T cells may contribute to poor immunoglobulin production in the newborn. Eur J Immunol (1994) 1.06
Combined immunodeficiencies due to defects in signal transduction: defects of the gammac-JAK3 signaling pathway as a model. Immunobiology (2000) 1.06
Preliminary phase I study of 4'-epi-adriamycin. Cancer Treat Rep (1979) 1.06
Autoantibodies in juvenile dermatomyositis. Clin Exp Rheumatol (1990) 1.06
Quantitative GLC determination of cyclophosphamide and isophosphamide in biological specimens. J Pharm Sci (1974) 1.05
Human peripheral blood hematopoietic progenitors are optimal targets of retroviral-mediated gene transfer. Blood (1992) 1.05
Lymphoid neogenesis in juvenile idiopathic arthritis correlates with ANA positivity and plasma cells infiltration. Rheumatology (Oxford) (2006) 1.05
Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clin Exp Rheumatol (1999) 1.04
IgM and IgD concentrations in the serum and secretions of children with selective IgA deficiency. Clin Exp Immunol (1983) 1.03
Prevalence of anticardiolipin antibodies in juvenile chronic arthritis. Ann Rheum Dis (1991) 1.03
Minimal residual disease in acute lymphoblastic leukemia detected by immune selection and gene rearrangement analysis. J Clin Oncol (1989) 1.02
Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis (2001) 1.02
First-line single-agent cetuximab in patients with advanced colorectal cancer. Ann Oncol (2007) 1.01
Clinical and genetic characterization of Italian patients affected by CINCA syndrome. Rheumatology (Oxford) (2006) 1.01
Extracellular enzymatic activity profiles in yeast and yeast-like strains isolated from tropical environments. J Appl Microbiol (2002) 1.01
Oral complications of pediatric hematopoietic cell transplantation: diagnosis and management. Support Care Cancer (2000) 1.01
Long-term clinical profile of children with the low-penetrance R92Q mutation of the TNFRSF1A gene. Arthritis Rheum (2011) 1.00
Immunodeficiency in Down's syndrome: T-lymphocyte subset imbalance in trisomic children. Clin Exp Immunol (1978) 1.00
Lymphocyte subpopulations in Down's syndrome: high percentage of circulating HNK-1+, Leu 2a+ cells. Clin Exp Immunol (1984) 1.00
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. Ann Oncol (2008) 0.99